ライフサイエンスコーパス: intravitreal

1 ellen equivalent) were randomized to receive intravitreal 0.5 mg ranibizumab monthly or according to

2 nts were randomly assigned (1:1) to repeated intravitreal aflibercept (2 mg/0.05 mL at baseline, 4 we

3 To report 2-year treatment outcomes with intravitreal aflibercept for neovascular age-related mac

4 open-label, investigator-sponsored trial of intravitreal aflibercept for polypoidal choroidal vascul

5 r intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of decreased visi

6 r intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of decreased visi

7 e diabetic retinopathy who were treated with intravitreal aflibercept had an improved outcome at 1 ye

8 ectively evaluate the efficacy and safety of intravitreal aflibercept in polypoidal choroidal vasculo

9 al Injection of Triamcinolone Acetonide with Intravitreal Aflibercept in Subjects with Macular Edema

10 Treatment with intravitreal aflibercept injection (2 mg) every 8 weeks

11 Interventions: Treatment with intravitreal aflibercept injection (2 mg) every 8 weeks

12 izumab 0.5 mg every 4 weeks (Rq4) (n = 595), intravitreal aflibercept injection (IAI) 2 mg every 4 we

13 VIVID randomized 872 DME patients to receive intravitreal aflibercept injection (IAI) 2 mg every 4 we

14 Conclusions and Relevance: Intravitreal aflibercept injection improves visual and a

15 Intravitreal aflibercept injection improves visual and a

16 rol eyes in 2 phase 3 trials-VISTA (Study of Intravitreal Aflibercept Injection in Patients With Diab

17 rol eyes in 2 phase 3 trials-VISTA (Study of Intravitreal Aflibercept Injection in Patients With Diab

18 ents With Diabetic Macular Edema) and VIVID (Intravitreal Aflibercept Injection in Vision Impairment

19 ents With Diabetic Macular Edema) and VIVID (Intravitreal Aflibercept Injection in Vision Impairment

20 s from baseline in these eyes at the time of intravitreal aflibercept injection initiation (an increa

21 At the time of intravitreal aflibercept injection initiation, these eye

22 etters from the initiation of treatment with intravitreal aflibercept injection through week 100.

23 The median time from week 24 to the first intravitreal aflibercept injection treatment was 34.0 (V

24 Intravitreal aflibercept injection was generally well to

25 zed to laser control received treatment with intravitreal aflibercept injection.

26 tantial vision loss receiving treatment with intravitreal aflibercept injection.

27 zed to laser control received treatment with intravitreal aflibercept injection.

28 tantial vision loss receiving treatment with intravitreal aflibercept injection.

29 laser control eyes receiving treatment with intravitreal aflibercept injection.

30 laser control eyes receiving treatment with intravitreal aflibercept injection.

31 the efficacy and safety achieved with 2.0 mg intravitreal aflibercept injections (IAIs) for diabetic

32 rcept (monotherapy arm), followed by monthly intravitreal aflibercept injections in both arms based o

33 Intravitreal aflibercept results in stabilization of vis

34 Intravitreal aflibercept TAE therapy led to significant

35 We report the 1 year safety and efficacy of intravitreal aflibercept.

36 ive NVAMD were managed with a TAE regimen of intravitreal aflibercept.

37 s, or conditions requiring treatment with an intravitreal agent or photocoagulation) were significant

38 O which had not responded to laser and other intravitreal agents.

39 Intravitreal and topical delivery of the DIO2 inhibitor

40 To characterize the first 10 years of intravitreal anti-vascular endothelial growth factor (VE

41 Intravitreal anti-vascular endothelial growth factor med

42 ransplant recipients undergoing therapy with intravitreal anti-VEGF agents, proteinuria be checked mo

43 The reason for intravitreal anti-VEGF injection and the involvement of

44 A total of 1182 individuals had an intravitreal anti-VEGF injection included in this analys

45 All consecutive patients treated with intravitreal anti-VEGF injection over a 1-month period w

46 e: (1) observation (i.e., no treatment); (2) intravitreal anti-VEGF injection; (3) verteporfin photod

47 investigated the adverse effect of multiple intravitreal anti-VEGF injections (200 ng/mul/eye anti-m

48 Intravitreal anti-VEGF injections are widely used in the

49 als, was used to identify patients receiving intravitreal anti-VEGF injections based on Current Proce

50 To estimate the need for bilateral intravitreal anti-VEGF injections in patients treated fo

51 Prior intravitreal anti-VEGF injections were associated with a

52 Total and annual numbers of intravitreal anti-VEGF injections, as well as injections

53 of patients had prior therapy with multiple intravitreal anti-VEGF injections.

54 Early intervention with intravitreal anti-VEGF medication and panretinal photoco

55 ent level II and III evidence indicates that intravitreal anti-VEGF therapy is as effective as laser

56 llograft dysfunction after the initiation of intravitreal anti-VEGF therapy.

57 in the pathology requiring a treatment with intravitreal anti-VEGF were recorded.

58 invasive procedures (vitreous biopsy and/or intravitreal antibiotic administration and/or vitrectomy

59 l treatment strategies were vitreous tap and intravitreal antibiotic injection (n = 5) and pars plana

60 ction (n = 5) and pars plana vitrectomy with intravitreal antibiotic injection (n = 5).

61 y 67015, 67025), a vitrectomy (67036), or an intravitreal antibiotic injection on the same day, betwe

62 s, and treatment most often consists of both intravitreal antibiotic injections and surgery.

63 All eyes were treated with intravitreal antibiotics and 4 underwent vitrectomy.

64 Intravitreal antibiotics treated the infection successfu

65 antibiotics and pars plana vitrectomies with intravitreal antibiotics.

66 Intravitreal antifungal injection, pars plana vitrectomy

67 ded systemic antifungals in all patients and intravitreal antifungals in 9 eyes.

68 systemic antimicrobial era, and the current intravitreal antimicrobial era.

69 r (VEGF) pharmacotherapies for ME, including intravitreal bevacizumab (5), aflibercept (2), and ranib

70 assess the optimal interval of preoperative intravitreal bevacizumab (IVB) administration in diabeti

71 To evaluate the outcomes of intravitreal bevacizumab (IVB) use in patients with a vi

72 Two eyes received intravitreal bevacizumab (range 3-6) injections, one of

73 Intravitreal bevacizumab can be effective in the managem

74 treal silicone oil droplets in the eye after intravitreal bevacizumab injections from a single specia

75 Over a 14-month period involving 6632 intravitreal bevacizumab injections, 60 cases (35 [58%]

76 Intravitreal bevacizumab is a frequently used antivascul

77 ed clinical trial designed to assess whether intravitreal bevacizumab is noninferior to intravitreal

78 SCORE2 was designed to assess whether intravitreal bevacizumab is noninferior to intravitreal

79 Intravitreal bevacizumab monotherapy in 241 infants (471

80 e this development between eyes treated with intravitreal bevacizumab or laser photocoagulation (LPC)

81 their patients on the risk of floaters with intravitreal bevacizumab preloaded in insulin syringes.

82 Treating ROP with intravitreal bevacizumab results in a characteristic sca

83 Intravitreal bevacizumab therapy for ROP is associated w

84 ntral retinal or hemiretinal vein occlusion, intravitreal bevacizumab was noninferior to aflibercept

85 ence of presumed silicone oil droplets after intravitreal bevacizumab was prepared in insulin syringe

86 Single or repeated doses of intravitreal bevacizumab were not shown to increase the

87 Endophthalmitis following intravitreal bevacizumab, ranibizumab, and aflibercept i

88 Treatment-naive RVO-ME receiving monthly intravitreal bevacizumab.

89 d case-control study, repeated injections of intravitreal bevacizumab.

90 (VEGF) inhibitor and 5644 subjects receiving intravitreal bevacizumab.

91 ohort study, patients who received the first intravitreal bevacizumab; for the nested case-control st

92 Eligible participants were randomized 1:1 to intravitreal brolucizumab (6 mg/50 mul) or aflibercept (

93 Intravitreal chemotherapy has emerged as an important mo

94 uperoxide burst was significantly reduced by intravitreal cobalamin and resulted in increased RGC sur

95 Three eyes received intravitreal corticosteroids and had final visual acuiti

96 Level I evidence also indicates that intravitreal corticosteroids are effective and safe for

97 ce was identified in 6 studies that examined intravitreal corticosteroids, including triamcinolone (4

98 ears, the iris prosthesis was explanted, and intravitreal cultures showed P. acnes growth after 5 day

99 However, intravitreal delivery of HS-ablated recombinant AAV2 (rA

100 tion route for ocular gene therapy is met by intravitreal delivery, but delivery of AAV by this route

101 design strategy for engineering capsids for intravitreal delivery.

102 vestigated OCT biomarkers for DME treated by intravitreal dexamethasone (DEX) implant.

103 eatment of OD with intravitreal ganciclovir, intravitreal dexamethasone and systemic prednisone, the

104 ity using OCTA at baseline and 60 days after intravitreal dexamethasone implant (IVDEX).

105 records of eyes with DME treated with 0.7 mg intravitreal dexamethasone implant and minimum 18-month

106 mine whether early visual acuity response to intravitreal dexamethasone implant therapy in diabetic m

107 Intravitreal dexamethasone implant was shown to prevent

108 s due to ischemia that did not recover after intravitreal dexamethasone implant.

109 ented during pregnancy responded promptly to intravitreal dexamethasone therapy by foveal thickness r

110 Intravitreal dexamethasone was used in 50 of 63 (79%) ey

111 Concerns have been raised that intravitreal dosing of vascular endothelial growth facto

112 Intravitreal drugs used in the study were ranibizumab (5

113 Three participants received a single intravitreal E10030 (0.03 mg) injection and were subsequ

114 Intravitreal E10030 administered at doses up to 3 mg in

115 All doses of intravitreal E10030 administered in combination with ran

116 performed cataract surgery, and at least 10 intravitreal (excluding bevacizumab) injections was cond

117 evidence suggesting that the combination of intravitreal foscarnet and systemic antiviral therapy ma

118 The adjunctive use of intravitreal foscarnet may be more effective than system

119 Retinal Vasculitis are oral corticosteroids, intravitreal ganciclovir and laser photocoagulation or v

120 g the first 4 months of treatment of OD with intravitreal ganciclovir, intravitreal dexamethasone and

121 Here we report a method to extend the intravitreal half-life of protein drugs as an alternativ

122 Thirty-one patients (14.3%) experienced intravitreal hemorrhage, of whom 9 (4.1%) required vitre

123 Dexamethasone intravitreal implant (DEX implant) is a sustained-releas

124 e of endophthalmitis following dexamethasone intravitreal implant (DEX) has varied in large clinical

125 A fluocinolone acetonide intravitreal implant (Retisert) was implanted in both ey

126 Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) was approved for t

127 Each patient was treated with a DEX 0.7 mg intravitreal implant and underwent phacoemulsification w

128 Dexamethasone intravitreal implant injection was given 10 times in 9 e

129 trophic factor released continuously from an intravitreal implant led to loss of total visual field s

130 Intravitreal implantation of color-coded retinoblastoma

131 h vehicle, and maintained for 10 days before intravitreal infection with S. pneumoniae E353.

132 ncomycin via intracameral bolus (33/36), via intravitreal injection (1/36), or through the irrigation

133 ), post-glaucoma implant (6/19, 31.6%), post-intravitreal injection (2/19, 10.5%), endogenous endopht

134 uring cataract surgery in eyes with previous intravitreal injection (IVI).

135 -up visits were performed 1 month after each intravitreal injection and included OCT analysis to eval

136 was 100% regression of vitreous seeds after intravitreal injection and no eye was treated with radia

137 iltrate cells in the EAU mice after a single intravitreal injection at the onset of peak disease.

138 d Medicaid Services was used to identify all intravitreal injection claims and anti-VEGF drug claims

139 elivery may become a safe alternative to the intravitreal injection for chronic retinal diseases such

140 mber 2016, nonpriming the syringe before the intravitreal injection had a higher risk of intravitreal

141 us disease in zone II, were treated with one intravitreal injection of 0.03 ml ranibizumab.

142 42 eyes), 1 eye was randomized to receive an intravitreal injection of 0.5 mg bevacizumab; the fellow

143 Intravitreal injection of 2-ME (in the two concentration

144 ose of study was to evaluate the efficacy of intravitreal injection of 2-Methoxyestradiol (2-ME) nano

145 Intravitreal injection of 2-Methoxyestradiol nanoemulsio

146 spective open-label, unilateral single-dose, intravitreal injection of AAV2(Y444,500,730F)-P1ND4v2 pe

147 a suprachoroidal injection of CLS-TA with an intravitreal injection of aflibercept (combination arm)

148 of aflibercept (combination arm) or only an intravitreal injection of aflibercept (monotherapy arm),

149 It was further demonstrated that intravitreal injection of an MCP-1-neutralizing antibody

150 initial treatment was a vitreous culture and intravitreal injection of antibiotics in 28 of 36 patien

151 Eyes were randomized to receive intravitreal injection of bevacizumab (1.25 mg; n = 182)

152 odds of developing endophthalmitis after an intravitreal injection of bevacizumab compared with rani

153 Initial treatment with either a single intravitreal injection of bevacizumab in off-label use (

154 outcome at age 4 years of eyes treated with intravitreal injection of bevacizumab with fellow eyes t

155 Eyes were randomly assigned to receive an intravitreal injection of bevacizumab, 1.25 mg, or aflib

156 A pars plana vitrectomy with intravitreal injection of ceftazidime (2 mg/0.1 ml) and

157 Intravitreal injection of DAD restored retinal light res

158 C57BL/6J mice received an intravitreal injection of Edn2 or control vehicle to exa

159 Intravitreal injection of IL-4 and IL-10 ameliorated RPE

160 Intravitreal injection of miR200-b DNA NPs significantly

161 Intravitreal injection of neutralizing antibodies agains

162 Patients were treated with a single intravitreal injection of Ocriplasmin (Jetrea, Thromboge

163 A single intravitreal injection of ocriplasmin 125 mug or placebo

164 In clinical practice, intravitreal injection of ocriplasmin achieved VMT relea

165 TG-MV-007, respectively) to receive a single intravitreal injection of ocriplasmin, 125 mug, or place

166 lopment of CNV which was treated by a single intravitreal injection of ranibizumab (0.5 mg/0.05 mL).

167 A single intravitreal injection of ranibizumab had a long-lasting

168 Patients received a single intravitreal injection of RTH258 0.5 mg (n = 11), 3.0 mg

169 eanwhile, the RGC count was higher following intravitreal injection of SCH442416 in the COH rats than

170 a typical case of AZOOR, suggesting that the intravitreal injection of steroid may benefit in certain

171 High variation was observed in intravitreal injection rates and in Medicare drug paymen

172 metic Fab-PEG-Fab (FpFinfliximab) for direct intravitreal injection to assess whether such formulatio

173 tinuous variable, the odds ratio for PCR per intravitreal injection was 1.04 (P = 0.016) after adjust

174 After logistic regression, prior intravitreal injection was associated with an increased

175 Intravitreal injection with the gene therapy vector AAV2

176 remarkable improvement was noticed after the intravitreal injection(IVI) of Ozurdex, consistent with

177 hich 1035 (1.64%) were in eyes with previous intravitreal injection(s).

178 After intravitreal injection, bevacizumab can be detected in s

179 ory of RD or retinal break, endophthalmitis, intravitreal injection, choroidal retinal vitreal biopsy

180 NPV (88.6%-100%) including billing codes for intravitreal injection, focal laser, panretinal photocoa

181 mediate transduction following noninvasive, intravitreal injection.

182 d RGCs into uninjured rat retinas in vivo by intravitreal injection.

183 ment with HORV 1 to 21 days after surgery or intravitreal injection.

184 d by Current Procedural Terminology codes on intravitreal injections (67028), retinal OCT imaging (92

185 Data were searched for all intravitreal injections (Current Procedural Terminology

186 Intravitreal injections (IVI) of anti-vascular endotheli

187 ious and noninfectious endophthalmitis after intravitreal injections (IVTs) of anti-vascular endothel

188 Intravitreal injections accounted for 0.55% of all vitre

189 Given the frequency of intravitreal injections and cataract surgery, increased

190 of anxiety were fear of going blind owing to intravitreal injections and concerns about treatment eff

191 rate of FFS Medicare beneficiaries receiving intravitreal injections and the mean Medicare-allowed dr

192 Repeat analysis considering intravitreal injections as a categoric variable showed 1

193 By considering the number of previous intravitreal injections as a continuous variable, the od

194 accept a high treatment burden with regular intravitreal injections at short intervals and long peri

195 A total of 5 patients (2.2%) received intravitreal injections following funduscopic screening.

196 2, 2008 to June 30, 2013, a total of 316,576 intravitreal injections from 25 French ophthalmic center

197 dophthalmitis), our analysis involved 383810 intravitreal injections given to 58612 patients.

198 The review assessed 4488 intravitreal injections in the 3-month period before (Ma

199 Intravitreal injections increased by 89 563%.

200 A history of intravitreal injections may be a risk factor for catarac

201 ked criteria, for example, minimum number of intravitreal injections of a specific drug and visual ac

202 Intravitreal injections of amikacin (0.4 mg/0.1 mL) were

203 was observed with ocular therapies including intravitreal injections of anti-vascular endothelial gro

204 incidence of presumed endophthalmitis after intravitreal injections of anti-vascular endothelial gro

205 All patients received at least 3 monthly intravitreal injections of anti-VEGF agents.

206 Intravitreal injections of anti-VEGF medications increas

207 Vitreous cultures with intravitreal injections of antibiotics and pars plana vi

208 al visual loss developed after they received intravitreal injections of autologous adipose tissue-der

209 From a total of 96 eyes treated with intravitreal injections of bevacizumab (10.5 +/- 7.6 (me

210 -control study between patients who received intravitreal injections of bevacizumab as the sole treat

211 All included patients had received intravitreal injections of bevacizumab, ranibizumab, or

212 -3 study, patients with DME received monthly intravitreal injections of either 0.5 or 2.0 mg ranibizu

213 owering general retinal MMP activity through intravitreal injections of GM6001 after ONC strongly red

214 lt zebrafish of both sexes were subjected to intravitreal injections of ouabain, which destroys the i

215 ivery to the posterior eye segment relies on intravitreal injections of therapeutics.

216 Intravitreal injections of these peptides and PEDF in th

217 Five patients were imaged before and after intravitreal injections of vascular endothelial growth f

218 A single dose of SRT significantly reduces intravitreal injections over 2 years.

219 An audit of intravitreal injections performed by retinal specialists

220 All patients who received subsequent intravitreal injections received PI prophylaxis without

221 outcomes in beneficiaries with a history of intravitreal injections relative to those without were c

222 re recommended in patients with a history of intravitreal injections undergoing cataract extraction.

223 rate of FFS Medicare beneficiaries receiving intravitreal injections varied widely by 7-fold across s

224 For each center, the number of intravitreal injections was determined using billing cod

225 Relative proportions of the drugs used for intravitreal injections were calculated and frequencies

226 A total of 40 535 intravitreal injections were performed by 7 retinal spec

227 taract surgeon grade, and number of previous intravitreal injections were significant predictors of P

228 Intravitreal injections were the primary driver of growt

229 udative form of the disease require repeated intravitreal injections which may be painful, are incomp

230 Patients were assigned randomly to receive intravitreal injections with either ranibizumab 0.5 mg o

231 ti-vascular endothelial growth factor (VEGF) intravitreal injections without improvement.

232 The mean number of intravitreal injections without PI before the developmen

233 720 721 procedures [eg, surgery], and 45 416 intravitreal injections) were stored, including 81 274 o

234 rs for PCR were age, sex, number of previous intravitreal injections, indication for intravitreal the

235 ving anti-vascular endothelial growth factor intravitreal injections, which transiently increase IOP.

236 rgoing cataract surgery after multiple prior intravitreal injections.

237 surgery for beneficiaries with a history of intravitreal injections.

238 d by anti-vascular endothelial growth factor intravitreal injections.

239 ed, including prior occurrence and number of intravitreal injections.

240 ld be rescued in CNGA3(-/-)/Nrl(-/-) mice by intravitreal (IVit) delivery of tyrosine to phenylalanin

241 V) enabled broad retinal targeting following intravitreal (IVT) injection, as exosomes have been show

242 AMD) over a 6month period following a single intravitreal (IVT) injection.

243 transduce the retina following noninvasive, intravitreal (Ivt) injection.

244 duction of experimental uveitis with 10ng of intravitreal lipopolysaccharide.

245 ponse to intra-arterial melphalan treatment, intravitreal melphalan (8 mug in 0.05 mL) was injected u

246 been described as predictive of response to intravitreal melphalan (IVM) in patients treated predomi

247 ction site after a single, standard low-dose intravitreal melphalan injection.

248 Significant ocular side effects following intravitreal melphalan injections are uncommon.

249 number, median dose, and cumulative dose of intravitreal melphalan injections required.

250 Intravitreal melphalan injections should be cautiously u

251 Intravitreal melphalan is an alternative to external bea

252 Intravitreal Mn administration to healthy rodents not on

253 areas of avascular/total retina (AVA) and of intravitreal neovascular/total retina (IVNV).

254 ntial vaso-obliteration followed by abnormal intravitreal neovascularization predisposing patients to

255 4 sham) randomized in a 2:1 ratio to receive intravitreal ocriplasmin 0.125 mg or sham injection.

256 Intravitreal ocriplasmin efficacy in the private practic

257 study of 58 eyes of 56 patients who received intravitreal ocriplasmin for VMT with or without full-th

258 Enzymatic vitreolysis with intravitreal ocriplasmin is another nonsurgical option,

259 However, the use of intravitreal of sustained-released steroid had not been

260 course of their treatment, and all received intravitreal or systemic antifungal therapy.

261 ly to previous clinical trials investigating intravitreal pharmacotherapy for treatment of CRVO-assoc

262 Current level I evidence suggests that intravitreal pharmacotherapy with anti-VEGF agents is ef

263 Test results from intravitreal preparations of bevacizumab acquired from c

264 03 mg) injection and were subsequently given intravitreal ranibizumab (0.5 mg) injections at weeks 2,

265 sed on indirect analyses: IVT-AFL 2q8 versus intravitreal ranibizumab (IVR) 0.5 mg as needed (PRN) (1

266 Intravitreal ranibizumab 0.5 mg or 2.0 mg monthly or pro

267 All subjects received intravitreal ranibizumab at baseline and at week 4, and

268 OCT 2000, initiated on a loading phase of 3 intravitreal ranibizumab injections and who had at least

269 al/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring las

270 oveal choroidal neovascularization receiving intravitreal ranibizumab or aflibercept over 12 months.

271 AMD who were switched from pro re nata (PRN) intravitreal ranibizumab to 8-weekly fixed aflibercept b

272 ated macular degeneration were randomized to intravitreal ranibizumab, 0.5 or 2.0 mg, administered mo

273 genesis of CNV in such cases and the role of intravitreal ranibizumab.

274 d 1 week and 1 month after administration of intravitreal ranibizumab.

275 th diabetic macular edema (DME) treated with intravitreal ranibizumab.

276 ctively treated in the study eye with 0.5 mg intravitreal ranibizumab.

277 Additionally, intravitreal SH-11037 (1 muM) significantly reduced chor

278 mab injections, 60 cases (35 [58%] women) of intravitreal silicone droplets were identified.

279 An increase in intravitreal silicone oil associated with bevacizumab pr

280 intravitreal injection had a higher risk of intravitreal silicone oil droplets compared with priming

281 was conducted of 60 patients who experienced intravitreal silicone oil droplets in the eye after intr

282 0 eyes]), with 126 eyes (30.0%) requiring an intravitreal tamponade and 49 eyes (11.7%) undergoing fu

283 9 eyes]), with 299 eyes (57.6%) requiring an intravitreal tamponade and 78 eyes (15.0%) undergoing fu

284 ations, of which 1935 had undergone previous intravitreal therapy (2.9%).

285 Previous intravitreal therapy is associated with a higher likelih

286 ade of healthcare professional administering intravitreal therapy, advanced cataract, and cataract su

287 ious intravitreal injections, indication for intravitreal therapy, grade of healthcare professional a

288 -binding mutants of AAV1 and AAV8 had higher intravitreal transduction than their non-HS-binding pare

289 All patients receiving intravitreal treatment between January 2011 and July 201

290 zed in a 1:1:1 ratio to 1 of the following 3 intravitreal treatment groups: E10030 0.3 mg in combinat

291 seline characteristics of patients receiving intravitreal treatment in the NIS OCEAN with those from

292 showed that antiangiogenic or corticosteroid intravitreal treatment led to reduced central foveal thi

293 Macular oedema responded to intravitreal treatment with triamcinolone.

294 The patient was treated with intravitreal triamcinolone (0.1 mL/4 mg).

295 Seven eyes received additional intravitreal vancomycin after surgery; 5 of these 7 eyes

296 n and ceftazidime in 59 of 63 (94%) eyes and intravitreal vancomycin and amikacin in 4 of 63 (6%) eye

297 The initial treatment included intravitreal vancomycin and ceftazidime in 59 of 63 (94%

298 Avoidance of additional intravitreal vancomycin is recommended if HORV is suspec

299 More than 99% of cases were treated with intravitreal vancomycin.

300 This inhibitory effect was comparable to intravitreal VEGF neutralization, and the protection aga